Advanced Filters
noise

Summit, New Jersey Clinical Trials

A listing of Summit, New Jersey clinical trials actively recruiting patient volunteers.

Found 370 clinical trials

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

18 years of age All Phase 2

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

The purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemia (AML) who have received standard chemotherapy and are planning to have an allogeneic hematopoietic stem cell …

18 years of age All Phase 2

A Study of Herbal Supplements in Cancer Survivors With Constipation

The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the …

18 years of age All Phase N/A

NEUROBALANCE Training to Improve Postural Control in Individuals With Traumatic Brain Injury

Our proposed study, "NEUROBALANCE," aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance functions in individuals with chronic traumatic brain injury (TBI). The study will recruit 45 participants who have had a TBI for over six months and experience …

18 - 75 years of age All Phase N/A
J Jeffrey N Feldman, MD

Atlantic Lipid Lowering Treatment Optimization Program

Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment …

18 - 120 years of age All Phase N/A

A Study of Tarlatamab for People With Prostate Cancer

The researchers are doing this study to find out whether tarlatamab is an effective treatment for DLL3-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

18 years of age Male Phase 2
V Vikram Shenoy Handiru, PhD

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

Our proposed study, "NEUROBALANCE Stroke,"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before …

18 - 75 years of age All Phase N/A

A Study of Tongue Strength and Endurance Using the Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer in People With Oral Tongue Cance

The purpose of this study is to learn more about tongue strength and endurance by using the Iowa Oral Performance Instrument (IOPI). The IOPI is a device that measures tongue pressure.

18 years of age All Phase N/A
S Site Public Contact

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used …

18 years of age All Phase 3
I In Gino, MD

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via …

18 years of age All Phase 2/3

Simplify language using AI